IPO
Vivoryon Therapeutics AG, will publish its third quarter financial results and a business update for the period ended September 30, 2019 on Thursday, November 28, 2019, in the form of an interim management report.
Pharnext SA, a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomics data and artificial intelligence, announced the establishment of an equity line facility to enhance the Company’s financial flexibility and improve liquidity for shareholders.
Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster.
Epigenomics AG announced its financial results for the first nine months of 2019.
Amarantus Bioscience Holdings, Inc. released a letter to its shareholders following the announcement of the binding term sheet to license the Company’s therapeutics subsidiaries’ technologies to Emerald Organic Products, an emerging CBD-focused health sciences company, and other recent events
Motif Bio plc of the Company held earlier in New York, all resolutions put to shareholders were duly passed.
Board includes experts from Case Western Reserve University, Duke University, University of Pittsburgh and Washington University in St. Louis
Establishing a New Gene Therapy Drug Process Development Building and Expanding Product Facilities in Texas, USA
ADL Bionatur Solutions, a company specialized in the research and development of health, cosmetic and beauty products, services and industrial fermentation production, reported financial results for the third quarter and first nine months of 2019.
Strategic investment in the US-based company complements Advanced MedTech’s non-invasive product portfolio and strengthens its leadership in urology and stone management
PRESS RELEASES